Looking Into the Future Today. Pharma 2030 and the Long-Term Planning Course
Russia has completed the first year of its Pharma-2030 strategy for the development of the pharmaceutical industry. According to the DSM Group, the size of the Russian pharmaceutical market increased to RUB 2.578 trillion in 2023. The Strategy Implementation Plan approved by the Russian government includes a wide range of measures to support the pharmaceutical industry with thorough planning for the next three years. However, the Long and Active Life national project that has been announced extends the planning horizon until 2030 due to the continued implementation and funding of federal projects to combat diabetes as well as cardiovascular, oncological, and infectious diseases. The government and business need to analyse the initial results and come up with proposals to modernize the Strategy, improve the drug regulation system, and update tools to support domestic pharmaceuticals, including innovative developments and the production of active pharmaceutical substances and ingredients for their creation. Russia must find ways to introduce innovative solutions, achieve technological sovereignty, and increase the share of domestic medicines. What results have the first year of the Strategy produced? What different approaches are needed due to the expanded planning horizon? What qualitative changes are crucial for the successful implementation of the country’s federal projects? Which unified coordinate system should be selected to predict the healthcare system’s demand for drugs? What are the most effective measures to support the pharmaceutical industry
Moderator
Aleksey Kedrin,
Chairman of the Board, Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (EAEU)
Panellists
Elena Astapenko,
Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation
Vilena Galkina,
Director for Relations with Government Authorities, Geropharm LLC
Dmitry Zaitsev,
General Director, Pharmstandard
Andrey Ivaschenko,
Chairman of the Board of Directors, ChemRar Group of Companies
Dmitry Kudlay,
Vice President for the Introduction of New Medical Technologies, Generium
Timofey Nizhegorodtsev,
Deputy Head, Federal Antimonopoly Service of the Russian Federation
Yevgeni Nifantiev,
Deputy Chairman of the State Duma Committee of the Federal Assembly of the Russian Federation of the Health Protection Committee
Ekaterina Priezzheva,
Deputy Minister of Industry and Trade of the Russian Federation
Aleksandr Semenov,
President, Active Component
Evgeniya Shapiro,
Director General, PSK Pharma
Lyudmila Scherbakova,
President, Velfarm Group of Companies
Front row participant
Victoria Galkovskaya,
Deputy Head, The Federal Service for Intellectual Property (Rospatent)